Sarepta Therapeutics Inc (SRPT)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -520,098 | -689,963 | -418,948 | -553,065 | -713,880 |
| Revenue | US$ in thousands | 1,243,340 | 933,013 | 701,887 | 540,099 | 380,833 |
| Pretax margin | -41.83% | -73.95% | -59.69% | -102.40% | -187.45% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-520,098K ÷ $1,243,340K
= -41.83%
The pretax margin of Sarepta Therapeutics Inc has shown significant improvement over the past five years. The company's pretax margin was -187.45% in 2019, indicating that the company was incurring significant losses before tax. However, there has been a steady improvement in the pretax margin since then.
In 2020, the pretax margin improved to -102.40%, followed by a further improvement to -59.69% in 2021. In 2022, there was a notable decline in the pretax margin to -73.95%, but the company managed to rebound in 2023 with a pretax margin of -41.83%.
Although the pretax margin continues to be negative, the trend of improvement over the years is a positive sign. The company's efforts to control costs and increase operational efficiency seem to be showing results. Continued focus on enhancing revenue and managing expenses could further enhance the pretax margin in the future.
Peer comparison
Dec 31, 2023